GNTA genenta.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The price chart on the GURU.Markets platform for Genenta Science S.p.A. (GNTA) shows an EV/EBITDA multiple of 0.00. The management of this European biotech is renowned for its scientific integrity and transparent reporting. Business development relies on the modification of macrophages using viral vectors to combat tumors. However, the absence of commercial drugs makes the valuation of the Italian startup dependent on the results of clinical trials.

This indicator measures the ratio of total enterprise value, including debt, to operating profit, allowing for an assessment of the real value of assets excluding the tax burden. For Genenta Science (GNTA), which invests in a costly staff of unique geneticists, the EV/EBITDA multiple valuation is critically important, as it correlates high operating personnel costs with the company's market capitalization.